Y-mAbs Therapeutics (YMAB) Competitors $8.59 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$8.59 0.00 (0.00%) As of 09/12/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock YMAB vs. TWST, VERA, AVDL, COGT, SNDX, JANX, SDGR, HROW, AMPH, and NUVBShould you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Twist Bioscience (TWST), Vera Therapeutics (VERA), Avadel Pharmaceuticals (AVDL), Cogent Biosciences (COGT), Syndax Pharmaceuticals (SNDX), Janux Therapeutics (JANX), Schrodinger (SDGR), Harrow (HROW), Amphastar Pharmaceuticals (AMPH), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. Y-mAbs Therapeutics vs. Its Competitors Twist Bioscience Vera Therapeutics Avadel Pharmaceuticals Cogent Biosciences Syndax Pharmaceuticals Janux Therapeutics Schrodinger Harrow Amphastar Pharmaceuticals Nuvation Bio Y-mAbs Therapeutics (NASDAQ:YMAB) and Twist Bioscience (NASDAQ:TWST) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership. Do analysts rate YMAB or TWST? Y-mAbs Therapeutics currently has a consensus price target of $9.62, suggesting a potential upside of 12.02%. Twist Bioscience has a consensus price target of $49.40, suggesting a potential upside of 95.18%. Given Twist Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Twist Bioscience is more favorable than Y-mAbs Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Y-mAbs Therapeutics 2 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 Which has more risk and volatility, YMAB or TWST? Y-mAbs Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500. Does the media prefer YMAB or TWST? In the previous week, Twist Bioscience had 14 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 19 mentions for Twist Bioscience and 5 mentions for Y-mAbs Therapeutics. Y-mAbs Therapeutics' average media sentiment score of 1.53 beat Twist Bioscience's score of 0.70 indicating that Y-mAbs Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Y-mAbs Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Twist Bioscience 8 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Is YMAB or TWST more profitable? Twist Bioscience has a net margin of -23.51% compared to Y-mAbs Therapeutics' net margin of -26.03%. Y-mAbs Therapeutics' return on equity of -24.60% beat Twist Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Y-mAbs Therapeutics-26.03% -24.60% -18.89% Twist Bioscience -23.51%-29.03%-21.77% Which has preferable valuation & earnings, YMAB or TWST? Y-mAbs Therapeutics has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Y-mAbs Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioY-mAbs Therapeutics$85.39M4.57-$29.67M-$0.50-17.18Twist Bioscience$362.27M4.22-$208.73M-$1.45-17.46 Do institutionals & insiders hold more shares of YMAB or TWST? 70.8% of Y-mAbs Therapeutics shares are held by institutional investors. 19.7% of Y-mAbs Therapeutics shares are held by company insiders. Comparatively, 3.0% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryY-mAbs Therapeutics beats Twist Bioscience on 9 of the 16 factors compared between the two stocks. Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart YMAB vs. The Competition Export to ExcelMetricY-mAbs TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$390.31M$3.19B$5.85B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-17.1821.4375.4125.98Price / Sales4.57429.44515.81181.13Price / CashN/A46.6837.5660.44Price / Book4.199.6112.156.29Net Income-$29.67M-$53.29M$3.29B$271.07M7 Day Performance0.12%0.13%0.74%3.87%1 Month Performance0.94%5.61%4.81%4.88%1 Year Performance-37.48%10.49%60.57%26.12% Y-mAbs Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)YMABY-mAbs Therapeutics2.0828 of 5 stars$8.59flat$9.62+12.0%-35.1%$390.31M$85.39M-17.18150News CoveragePositive NewsTWSTTwist Bioscience3.9649 of 5 stars$26.25+1.9%$49.40+88.2%-43.2%$1.55B$312.97M-18.10990News CoverageVERAVera Therapeutics3.044 of 5 stars$24.75+2.3%$63.00+154.5%-33.3%$1.54BN/A-6.9140Positive NewsAVDLAvadel Pharmaceuticals2.8943 of 5 stars$15.38-2.4%$20.86+35.6%+10.4%$1.53B$221.08M-512.6770COGTCogent Biosciences2.8671 of 5 stars$12.68-2.8%$20.00+57.7%+23.3%$1.49BN/A-7.1280Positive NewsSNDXSyndax Pharmaceuticals3.9113 of 5 stars$16.33-4.2%$38.89+138.1%-13.6%$1.47B$23.68M-4.20110Analyst ForecastJANXJanux Therapeutics2.4909 of 5 stars$24.81+3.5%$85.55+244.8%-48.3%$1.44B$10.59M-13.7830News CoverageAnalyst ForecastSDGRSchrodinger3.3918 of 5 stars$19.44+1.6%$27.83+43.2%-9.8%$1.41B$207.54M-7.84790Positive NewsHROWHarrow3.0726 of 5 stars$39.77+7.5%$64.67+62.6%-6.3%$1.37B$199.61M-159.08180Trending NewsAnalyst RevisionGap UpAMPHAmphastar Pharmaceuticals3.8618 of 5 stars$29.26-0.5%$31.60+8.0%-39.7%$1.37B$731.97M10.962,028Positive NewsNUVBNuvation Bio2.5989 of 5 stars$3.48-10.9%$7.50+115.8%+3.0%$1.33B$7.87M-5.5260High Trading Volume Related Companies and Tools Related Companies TWST Competitors VERA Competitors AVDL Competitors COGT Competitors SNDX Competitors JANX Competitors SDGR Competitors HROW Competitors AMPH Competitors NUVB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:YMAB) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
